<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF THE GENOME THERAPEUTICS CORPORATION FOR THE THREE MONTHS
ENDED NOVEMBER 25, 1995 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>
<RESTATED> 
<MULTIPLIER> 1
<CURRENCY> US DOLLARS
       
                             
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          AUG-31-1995
<PERIOD-START>                             AUG-31-1995
<PERIOD-END>                               NOV-25-1995
<EXCHANGE-RATE>                                      1
<CASH>                                       2,276,648
<SECURITIES>                                 5,712,936
<RECEIVABLES>                                  570,449
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             8,640,420
<PP&E>                                       4,779,834
<DEPRECIATION>                               2,576,123
<TOTAL-ASSETS>                              11,743,806
<CURRENT-LIABILITIES>                        3,502,522
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     7,071,572
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                11,743,806
<SALES>                                         12,565
<TOTAL-REVENUES>                             2,213,379
<CGS>                                              506
<TOTAL-COSTS>                                1,282,684
<OTHER-EXPENSES>                             1,592,444
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              40,740
<INCOME-PRETAX>                              (661,749)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                          (661,479)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (661,479)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0